Infliximab Therapy Improves Health Related Quality of Life in Ulcerative Colitis Patients
Brian G. Feagan(Western University), William J. Sandborn(University of San Diego), P. Rutgeerts, S. B. Hanauer(University of Chicago), S. Yan, D. Eisenberg, Jewel Johanns(Johnson & Johnson (United States)), Adriana Segura Olson
Cited by 5
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k